Earnings, Q3 FY2026Strong growth drivers lifted Q3 profit and FY2026 guidance despite pipeline setbacks.Earnings releaseSlidesCall transcriptInterim report
Investor updateRemibrutinib combines strong RMS trial results with $4bn-plus sales potential.SlidesEvent transcript
Earnings, Q2 FY2026Q2 delivered sales growth and strong brand momentum, with full-year guidance reaffirmed.Earnings releaseSlidesCall transcriptInterim report
Earnings, Q1 FY2026Priority brands delivered robust growth, supporting a positive long-term outlook despite generic headwinds.Earnings releaseSlidesCall transcriptInterim report
Investor presentationLarge patient populations across major diseases highlight ongoing unmet needs in advanced therapies.Slides
AGM 2026Shareholders approved all proposals amid strong results, dividend growth, and strategic focus.Event transcript
44th Annual J.P. Morgan Healthcare ConferenceStrong pipeline, commercial execution, and innovation drive long-term growth and value.SlidesEvent transcript
Earnings, Q4 FY2025AnnualAchieved 8% sales growth, 40.1% core margin, and record free cash flow, with strong brand momentum.Earnings release20-FAnnual reportAnnual reportSlidesCall transcriptInterim report
Status UpdateAdvancing Global Health, access, and sustainability with innovation, partnerships, and measurable impact.SlidesEvent transcript
Investor Update Part 2Disciplined M&A, robust cash flow, and AI-driven efficiency underpin long-term growth.SlidesEvent transcriptPress release
Investor Update Part 1Upgraded growth guidance and a catalyst-rich pipeline drive strong long-term outlook.SlidesEvent transcriptPress release
Earnings, Q4 FY2024AnnualEarnings release20-FAnnual reportAnnual reportSlidesCall transcriptInterim report